CUMBERLAND PHARMACEUTICALS INC - 8-K Filing

Cumberland Pharmaceuticals plans to submit a New Drug Application (NDA) for ifetroban as a treatment for Duchenne muscular dystrophy (DMD) cardiomyopathy.

SEC EDGAR ·

Tickers: $CPIX

Read the full article at SEC EDGAR

More Regulatory news